Thr17

Site Information
SAIRRAstIEMPQQA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448115

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 63 ) , immunoprecipitation ( 61 ) , mass spectrometry ( 14 , 21 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ) , mutation of modification site ( 15 , 16 , 24 , 57 , 59 , 61 ) , peptide sequencing ( 63 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 24 , 25 , 56 , 57 , 58 , 60 , 61 , 62 ) , phosphoamino acid analysis ( 63 ) , phosphopeptide mapping ( 63 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 24 , 25 , 56 , 57 , 58 , 60 , 62 )
Relevant cell line - cell type - tissue:	'heart, ventricle' ( 7 , 8 ) , 'muscle, smooth' ( 56 ) , 'stem, induced pluripotent' ( 5 , 7 ) , 293 (epithelial) ( 16 ) , cardiac-heart ( 10 , 16 ) , heart ( 1 , 3 , 6 , 9 , 12 , 15 , 17 , 21 , 22 , 24 , 26 , 29 , 30 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 53 , 54 , 55 , 58 , 60 , 63 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 14 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 14 ) , HL-1 (myocyte) ( 14 ) , kidney ( 26 ) , liver ( 31 , 32 ) , lung ( 26 ) , myocyte ( 8 ) , myocyte-heart ( 2 , 4 , 5 , 7 , 11 , 13 , 18 , 19 , 20 , 25 , 57 , 59 , 61 ) , myocyte-heart [PLB (mouse), genetic knockin] ( 59 ) , myocyte-heart [PLB (mouse), homozygous knockout] ( 59 ) , myocyte-heart [SERCA2 (mouse), transfection] ( 62 ) , thymus ( 27 , 28 )

In vivo Characterization

Methods used to characterize site in vivo:

[32P] bio-synthetic labeling ( 63 ) , immunoprecipitation ( 61 ) , mass spectrometry ( 14 , 21 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ) , mutation of modification site ( 15 , 16 , 24 , 57 , 59 , 61 ) , peptide sequencing ( 63 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 24 , 25 , 56 , 57 , 58 , 60 , 61 , 62 ) , phosphoamino acid analysis ( 63 ) , phosphopeptide mapping ( 63 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 24 , 25 , 56 , 57 , 58 , 60 , 62 )

Relevant cell line - cell type - tissue:

'heart, ventricle' ( 7 , 8 ) , 'muscle, smooth' ( 56 ) , 'stem, induced pluripotent' ( 5 , 7 ) , 293 (epithelial) ( 16 ) , cardiac-heart ( 10 , 16 ) , heart ( 1 , 3 , 6 , 9 , 12 , 15 , 17 , 21 , 22 , 24 , 26 , 29 , 30 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 53 , 54 , 55 , 58 , 60 , 63 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 14 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 14 ) , HL-1 (myocyte) ( 14 ) , kidney ( 26 ) , liver ( 31 , 32 ) , lung ( 26 ) , myocyte ( 8 ) , myocyte-heart ( 2 , 4 , 5 , 7 , 11 , 13 , 18 , 19 , 20 , 25 , 57 , 59 , 61 ) , myocyte-heart [PLB (mouse), genetic knockin] ( 59 ) , myocyte-heart [PLB (mouse), homozygous knockout] ( 59 ) , myocyte-heart [SERCA2 (mouse), transfection] ( 62 ) , thymus ( 27 , 28 )

Upstream Regulation
Regulatory protein:	ADRB1 (mouse) ( 21 ) , CAMK2D (mouse) ( 60 ) , plakophilin 2 (mouse) ( 9 ) , PPP2R3A (human) ( 3 ) , SERCA2 (human) ( 2 ) , SERCA2 (mouse) ( 62 ) , Spinophilin (mouse) ( 16 ) , tafazzin (human) ( 7 ) , TNNT2 (human) ( 5 ) , TPM1 (mouse) ( 20 ) , TRPC7 (human) ( 8 )
Putative in vivo kinases:	CAMK2A (mouse) ( 6 , 7 , 19 , 24 ) , CAMK2D (mouse) ( 15 , 25 )
Kinases, in vitro:	CAMK2A (mouse) ( 61 ) , PKACA (mouse) ( 61 )
Treatments:	adriamycin ( 11 ) , autocamtide_inhibitory_peptide ( 7 , 17 , 58 ) , caffeine ( 25 ) , captopril ( 4 ) , cGMP_analog ( 56 ) , cyclopiazonic_acid ( 56 ) , dobutamine ( 58 ) , electrical_stimulation ( 57 ) , hydroxyurea ( 12 ) , imatinib ( 13 ) , inhibitor-1 ( 22 ) , ionizing_radiation ( 19 ) , ischemia/reperfusion ( 15 , 24 ) , isoproterenol ( 3 , 10 , 15 , 18 , 61 , 63 ) , KN-93 ( 24 , 25 , 56 , 57 ) , LPS ( 1 , 4 , 6 ) , MitoTEMPO ( 7 ) , ODQ ( 56 ) , phenylephrine ( 25 ) , resatorvid ( 6 ) , SNP ( 56 ) , vidarabine ( 1 ) , wheel running test ( 9 )

Downstream Regulation
Effects of modification on PLB:	activity, induced ( 8 , 24 , 57 , 59 )
Effects of modification on biological processes:	apoptosis, induced ( 1 , 4 )

Disease / Diagnostics Relevance
Relevant diseases:	ventricular tachycardia ( 24 )

References
1	Tsunoda M, et al. (2023) Vidarabine, an anti-herpes agent, improves Porphyromonas gingivalis lipopolysaccharide-induced cardiac dysfunction in mice. J Physiol Sci 73, 18 37558983 Curated Info
2	Gonnot F, et al. (2023) SERCA2 phosphorylation at serine 663 is a key regulator of Ca homeostasis in heart diseases. Nat Commun 14, 3346 37291092 Curated Info
3	Herting JR, et al. (2023) Hypercontractile cardiac phenotype in mice overexpressing the regulatory subunit PR72 of protein phosphatase 2A. Front Cardiovasc Med 10, 1239555 37868783 Curated Info
4	Kiyomoto K, et al. (2023) Oral angiotensin-converting enzyme inhibitor captopril protects the heart from Porphyromonas gingivalis LPS-induced cardiac dysfunction in mice. PLoS One 18, e0292624 37983238 Curated Info
5	Kondo T, et al. (2022) Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for Δ160E-Induced Cardiomyopathy. Circ Genom Precis Med 15, e003522 35861968 Curated Info
6	Matsuo I, et al. (2022) Role of TLR4 signaling on Porphyromonas gingivalis LPS-induced cardiac dysfunction in mice. PLoS One 17, e0258823 35648750 Curated Info
7	Liu X, et al. (2021) Increased Reactive Oxygen Species-Mediated Ca/Calmodulin-Dependent Protein Kinase II Activation Contributes to Calcium Handling Abnormalities and Impaired Contraction in Barth Syndrome. Circulation 143, 1894-1911 33793303 Curated Info
8	Liu X, et al. (2021) TRPC7 regulates the electrophysiological functions of embryonic stem cell-derived cardiomyocytes. Stem Cell Res Ther 12, 262 33941260 Curated Info
9	Hammer KP, et al. (2021) Beneficial effect of voluntary physical exercise in Plakophilin2 transgenic mice. PLoS One 16, e0252649 34086773 Curated Info
10	Werhahn SM, et al. (2021) Adaptive versus maladaptive cardiac remodelling in response to sustained β-adrenergic stimulation in a new 'ISO on/off model'. PLoS One 16, e0248933 34138844 Curated Info
11	Llach A, et al. (2019) Progression of excitation-contraction coupling defects in doxorubicin cardiotoxicity. J Mol Cell Cardiol 126, 129-139 30500377 Curated Info
12	Respress JL, et al. (2014) Long-term simulated microgravity causes cardiac RyR2 phosphorylation and arrhythmias in mice. Int J Cardiol 176, 994-1000 25227892 Curated Info
13	Barr LA, et al. (2014) Imatinib activates pathological hypertrophy by altering myocyte calcium regulation. Clin Transl Sci 7, 360-7 24931551 Curated Info
14	Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45 25162660 Curated Info
15	Di Carlo MN, et al. (2014) CaMKII-dependent phosphorylation of cardiac ryanodine receptors regulates cell death in cardiac ischemia/reperfusion injury. J Mol Cell Cardiol 74, 274-83 24949568 Curated Info
16	Chiang DY, et al. (2014) Impaired local regulation of ryanodine receptor type 2 by protein phosphatase 1 promotes atrial fibrillation. Cardiovasc Res 103, 178-87 24812280 Curated Info
17	Chakraborty A, et al. (2014) Inhibition of CaMKII Does Not Attenuate Cardiac Hypertrophy in Mice with Dysfunctional Ryanodine Receptor. PLoS One 9, e104338 25093823 Curated Info
18	Besser J, et al. (2014) MiRNA-1/133a Clusters Regulate Adrenergic Control of Cardiac Repolarization. PLoS One 9, e113449 25415383 Curated Info
19	Sag CM, et al. (2013) Ionizing radiation regulates cardiac Ca handling via increased ROS and activated CaMKII. Basic Res Cardiol 108, 385 24068185 Curated Info
20	Schulz EM, et al. (2013) Decreasing Tropomyosin Phosphorylation Rescues Tropomyosin-induced Familial Hypertrophic Cardiomyopathy. J Biol Chem 288, 28925-28935 23960072 Curated Info
21	Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11 23737553 Curated Info
22	Pritchard TJ, et al. (2013) Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts. PLoS One 8, e80717 24312496 Curated Info
23	Schulz EM, et al. (2012) Tropomyosin dephosphorylation results in compensated cardiac hypertrophy. J Biol Chem 287, 44478-89 23148217 Curated Info
24	Said M, et al. (2011) Calcium-calmodulin dependent protein kinase II (CaMKII): a main signal responsible for early reperfusion arrhythmias. J Mol Cell Cardiol 51, 936-44 21888910 Curated Info
25	Mishra S, et al. (2011) Location matters: clarifying the concept of nuclear and cytosolic CaMKII subtypes. Circ Res 109, 1354-62 21998325 Curated Info
26	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
27	Guo A (2009) CST Curation Set: 8170; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
28	Guo A (2009) CST Curation Set: 8169; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
29	Zhou J (2009) CST Curation Set: 7444; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
30	Zhou J (2009) CST Curation Set: 7445; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
31	Zhou J (2009) CST Curation Set: 7426; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST] Curated Info
32	Zhou J (2009) CST Curation Set: 7425; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST] Curated Info
33	Zhou J (2009) CST Curation Set: 7417; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST] Curated Info
34	Zhou J (2009) CST Curation Set: 7418; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST] Curated Info
35	Zhou J (2009) CST Curation Set: 7385; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
36	Zhou J (2009) CST Curation Set: 7386; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST] Curated Info
37	Stokes M (2008) CST Curation Set: 5664; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
38	Stokes M (2008) CST Curation Set: 5665; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
39	Stokes M (2008) CST Curation Set: 5168; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
40	Stokes M (2008) CST Curation Set: 5087; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
41	Stokes M (2008) CST Curation Set: 5088; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
42	Stokes M (2008) CST Curation Set: 5089; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
43	Stokes M (2008) CST Curation Set: 5090; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
44	Stokes M (2008) CST Curation Set: 5091; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
45	Stokes M (2008) CST Curation Set: 5092; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
46	Stokes M (2008) CST Curation Set: 5093; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
47	Stokes M (2008) CST Curation Set: 5094; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
48	Zhou J (2008) CST Curation Set: 4782; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988 Curated Info
49	Rikova K (2008) CST Curation Set: 4776; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-4/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
50	Rikova K (2008) CST Curation Set: 4772; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
51	Rikova K (2008) CST Curation Set: 4760; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
52	Rikova K (2008) CST Curation Set: 4762; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
53	Guo A (2007) CST Curation Set: 3118; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
54	Guo A (2007) CST Curation Set: 2923; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S/TD/EXD/E) Immunoaffinity Beads Cat#: 1994 Curated Info
55	Guo A (2007) CST Curation Set: 2829; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
56	Kim M, Perrino BA (2007) CaM kinase II activation and phospholamban phosphorylation by SNP in murine gastric antrum smooth muscles. Am J Physiol Gastrointest Liver Physiol 292, G1045-54 17185633 Curated Info
57	Zhao W, et al. (2004) Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility. J Mol Cell Cardiol 37, 607-12 15276030 Curated Info
58	Ji Y, et al. (2003) Targeted inhibition of Ca2+/calmodulin-dependent protein kinase II in cardiac longitudinal sarcoplasmic reticulum results in decreased phospholamban phosphorylation at threonine 17. J Biol Chem 278, 25063-71 12692124 Curated Info
59	Li Y, Kranias EG, Mignery GA, Bers DM (2002) Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 90, 309-16 11861420 Curated Info
60	Zhang T, et al. (2002) The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 277, 1261-7 11694533 Curated Info
61	Chu G, et al. (2000) A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta -agonists. J Biol Chem 275, 38938-43 10988285 Curated Info
62	Ji Y, et al. (2000) Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function. J Biol Chem 275, 38073-80 10970890 Curated Info
63	Wegener AD, Simmerman HK, Lindemann JP, Jones LR (1989) Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. J Biol Chem 264, 11468-74 2544595 Curated Info